Kelsey A. Smith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kelsey A. Smith has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Dana Carina Baiu
Department of Medical Microbiology and Immunology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
19 shared publications - Eric Johannsen
Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States of America
19 shared publications - Huy Q. Dinh
McArdle Laboratory for Cancer Research, Department of Oncology, Carbone Cancer Center, University of Wisconsin-Madison, Madison, USA
19 shared publications - Jenny E. Gumperz
Department of Medical Microbiology and Immunology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
19 shared publications - Joshua Brand
University of Wisconsin 2 McArdle Laboratory for Cancer Research, Department of Oncology Madison, Wisconsin
19 shared publications - Makoto Ohashi
Department of Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
19 shared publications
Latest Publications
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Fig. S7. Fold-expansion of CD4 or CD8 T cells from HNSCC patient blood.
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Fig. S7. Fold-expansion of CD4 or CD8 T cells from HNSCC patient blood.
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Fig. S5. Detection of immunotherapeutic iNKT cells and DCs after injection into tumor bearing mice.
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Fig. S5. Detection of immunotherapeutic iNKT cells and DCs after injection into tumor bearing mice.
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Fig. S1. Analysis of tumor mass and immunotherapy effects as a function of mouse sex.
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Fig. S1. Analysis of tumor mass and immunotherapy effects as a function of mouse sex.
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Movie S3 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessMovie S3 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Differentially expressed genes
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Differentially expressed genes
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Fig. S9. Comparison of anti-tumor immunotherapeutic effect of iNKT-DCs generated using polyclonal vs. clonal CD4+ iNKT cells.
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Fig. S9. Comparison of anti-tumor immunotherapeutic effect of iNKT-DCs generated using polyclonal vs. clonal CD4+ iNKT cells.
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Movie S5 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Paired iNKT-DC migration example 1
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessMovie S5 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Paired iNKT-DC migration example 1
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Data from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Invariant NK T (iNKT) cells are a conserved T-lymphocyte population capable of acting on dendritic cells (DC) to potently amplify downstream immune responses. However, the processes underlying such iNKT adjuvancy remain poorly understood. In this study, we showed that allogeneic human CD4+ iNKT cells form stably adhered bi-cellular complexes with monocyte-derived DCs that migrated together as pairs and showed extended DC calcium signaling. Compared with DCs treated with the synthetic adjuvant monophosphoryl lipid A, DCs complexed with iNKT cells had elevated expression of MHC class I and multiple costimulatory molecules, including 4-1BBL, OX40L, and IL15Rα, whereas the iNKT cells expressed CD70. Consistent with this distinctive costimulatory profile, iNKT–DC complexes were efficient activators of CD8+ T cells. Administering iNKT–DC complexes as a cellular immunotherapy in a xenograft model of aggressive human B-cell lymphoma resulted in rapid reduction in tumor mass, antigen-specific B-cell clearance, and transcriptional activation indicative of enhanced T-cell proliferation and effector responses. iNKT–DC immunotherapy was effective at late stages of tumor progression that were refractory to immune checkpoint blockade immunotherapy, suggesting that the consortium of activating signals provided by iNKT–DC complexes rejuvenates exhausted antitumor immunity. Finally, allogeneic CD4+ iNKT cells formed similar complexes with monocyte-derived DCs from patients with head and neck cancer and promoted tumor antigen–dependent CD8+ T-cell activation. These results show that monocyte-derived DCs paired with allogeneic CD4+ iNKT cells act as a potent antitumor cellular immunotherapy that activates antigen-specific CD8+ T-cell immunity.
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
Invariant NK T (iNKT) cells are a conserved T-lymphocyte population capable of acting on dendritic cells (DC) to potently amplify downstream immune responses. However, the processes underlying such iNKT adjuvancy remain poorly understood. In this study, we showed that allogeneic human CD4+ iNKT cells form stably adhered bi-cellular complexes with monocyte-derived DCs that migrated together as pairs and showed extended DC calcium signaling. Compared with DCs treated with the synthetic adjuvant monophosphoryl lipid A, DCs complexed with iNKT cells had elevated expression of MHC class I and multiple costimulatory molecules, including 4-1BBL, OX40L, and IL15Rα, whereas the iNKT cells expressed CD70. Consistent with this distinctive costimulatory profile, iNKT–DC complexes were efficient activators of CD8+ T cells. Administering iNKT–DC complexes as a cellular immunotherapy in a xenograft model of aggressive human B-cell lymphoma resulted in rapid reduction in tumor mass, antigen-specific B-cell clearance, and transcriptional activation indicative of enhanced T-cell proliferation and effector responses. iNKT–DC immunotherapy was effective at late stages of tumor progression that were refractory to immune checkpoint blockade immunotherapy, suggesting that the consortium of activating signals provided by iNKT–DC complexes rejuvenates exhausted antitumor immunity. Finally, allogeneic CD4+ iNKT cells formed similar complexes with monocyte-derived DCs from patients with head and neck cancer and promoted tumor antigen–dependent CD8+ T-cell activation. These results show that monocyte-derived DCs paired with allogeneic CD4+ iNKT cells act as a potent antitumor cellular immunotherapy that activates antigen-specific CD8+ T-cell immunity.
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Movie S4 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessMovie S4 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Movie S1 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessMovie S1 from CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates